【摘要】 目的:研究18F-FDG PET/CT显像在卵巢癌术后随访中的价值及与血清CA125检测的关系。方法:对45例卵巢癌术后患者行18F-FDG PET/CT显像及血清CA125检测,与手术病理或临床随访结果比较判断其诊断复发、转移灶的准确性并比较二者之间的关系。结果:18F-FDG PET/CT显像诊断卵巢癌复发、转移的敏感性、特异性、准确性、阳性预测值、阴性预测值分别为90.3%(28/31)、92.8%(13/14)、91.1%(41/45)、96.5%(28/29)和81.5%(13/16)。血清CA125诊断卵巢癌复发、转移的敏感性、特异性、准确性、阳性预测值和阴性预测值分别为74.2%(23/31)、78.5%(11/14)、75.5%(34/45)、88.4%(23/26)和57.9%(11/19)。18F-FDG PET/CT显像与血清CA125检测结果有一定相关性,26例血清CA125升高者中23例PET/CT检查显示数目不等的复发;19例CA125正常患者,8例PET/CT检查显示复发,二者有显著性差异(χ2=11.007,P=0.001)。10例血清CA125≤100 U/mL的复发患者病灶数均较少,90%(9/10)为1～3个;21例CA125>100 U/mL复发患者病灶数80.9%(17/21)为3个以上,二者有显著性差异(χ2=14.006,P=0)。结论:18F-FDG PET/CT显像在卵巢癌术后随访中具有重要临床价值,与血清CA125检测有一定的相关性和互补性。更多还原

【Abstract】 Objective: To evaluate the value of 18F-FDG PET/CT imaging in the follow-up of ovarian cancer after surgery and the relationship between PET/CT imaging and serum CA125 assay.Methods: 18F-FDG PET/CT and serum CA125 assay were performed in 45 postoperative patients with ovarian cancer.The diagnostic value was determined according to the results of surgical pathology or clinical follow-up.Results: The sensitivity,specificity,accuracy,positive predictive value,negative predictive value of 18F-FDG PET/CT imaging for detecting ovarian cancer recurrence or metastasis were 90.3%(28/31),92.8%(13/14),91.1%(41/45),96.5%(28/29) and 81.5%(13/16),respectively.And the sensitivity,specificity,accuracy,positive predictive value,negative predictive value of serum CA125 assay for detecting ovarian cancer recurrence or metastasis were 74.2%(23/31),78.5%(11/14),75.5%(34/45),88.4%(23/26) and 57.9%(11/19),respectively.There was a correlation between 18F-FDG PET/CT imaging and serum CA125 assay.Among 26 patients with increased serum CA125,recurrent lesions were detected by 18F-FDG PET/CT in 23 patients.However,among 19 patients with normal CA125,only 8 patients were detected to have recurrent lesions by 18F-FDG PET/CT.The recurrence detected by 18F-FDG PET/CT was statistically different between increased serum CA125 group and normal CA125 group(χ2=11.007,P=0.001).Fewer recurrent lesions were found in 10 patients with serum CA125≤100 U/mL.In our study,90%(9/10) of patients with serum CA125≤100 U/mL had 1~3 recurrent lesions.More than 3 recurrent lesions were found in 21 patients with serum CA125>100 U/mL.The number of recurrent lesions was statistically different between the group with serum CA125≤100 U/mL and that with serum CA125>100 U/mL(χ2=14.006,P=0).Conclusion: 18F-FDG PET/CT possesses an important clinical priority for following-up patients with ovarian cancer after surgery.There was a correlation between 18F-FDG PET/CT imaging and serum CA125 assay.18F-FDG PET/CT and serum CA125 assay can complement each other.更多还原